Please login to the form below
CoStim Pharmaceuticals
This page shows the latest CoStim Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Novartis enters PD-1 race via CoStim acquisition
Expands presence in cancer immunotherapies. Novartis has reached a deal to acquire US company CoStim Pharmaceuticals, expanding its position in the hot topic of cancer immunotherapy. ... Boston, Massachusetts-based CoStim - which started operations in
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
Create Health
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
